This project has received €3.1 million in funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 738707.
ONCOCHECK is a two-year clinical project carried out by Life Length. ONCOCHECK’s objective is the clinical validation of Telomere Associated Variables (TAVs) as cancer biomarkers.
With over 7,000 peer-reviewed scientific and clinical journal articles, measuring telomere length as a biomarker for cancer diagnosis and prognosis is well established.
MORE THAN 5,000 INDIVIDUALS RECRUITED
32 HOSPITALS INVOLVED IN THE PROJECT
Thanks to the ONCOCHECK project results, now we are developing new applications in oncology for our TAT technology. All the TAVs (Telomere Associated Variables) obtained have been analyzed using massive data treatment aiming to generate algorithms that would improve cancer management.
The biggest study in terms of sample recruitment was the prostate cancer study. Therefore, the results obtained allowed the analysts to generate better prediction models than in the other pathologies. We are now developing the prostate cancer application as a risk score called ProsTAV.
As for the other studies, preliminary results are very encouraging and we believe we will be soon also exploring the development of new tests for other pathologies as lung or children cancer.